This month's talk will be given by Dr.Kirsch, MD
Senior Vice President, Translational Medicine Adaptive Biotechnologies Corp. and is the second in our series of presentations on clinical NGS.
Dr. Kirsch will be discussing Adaptive’s DNA immune receptor profiling technology and its application to monitoring minimal residual disease (MRD) in leukemia and lymphoma.
Adaptive Biotechnologies is at the forefront of immune repertoire profiling using next generation DNA sequencing combined with refined molecular and computational biology. The possible applications of this platform to clinical issues are manifold including MRD, immune reconstitution, autoimmunity, response to antigenic or immunogenic challenge, aging, allograft rejection, immunotherapy, antibody generation, and perhaps eventually, oncologic target selection and therapeutic development. The application of this approach to basic questions of immunology, evolution, and cancer biology are equally numerous. This presentation will review these broad areas of impact of immune repertoire diagnostics as the delineation of the diversity and clonal prevalence in a given blood or tissue sample is providing information of ever-increasing importance in clinical diagnosis and patient stratification.
After the talks we'll be walking down for a pint at "A Terrible Beauty" Irish pub at 1001 Fairview Avenue North # 1700 Seattle, WA 98109
Special thanks to Adaptive Biotechnologies Corp. for sponsoring and to Bob Livingston for arranging.
Afterwards we'll walk over to "A Terrible Beauty" Irish Pub for a pint.
Looking forward to seeing you there!